Chair: Prof. Peyman Hadji and Prof. Cyrille Confavreux

Members: A Bazzocchi,  E Biver, R Blank, JJ Body, ML Brandi, C Campusano, J Cannata-Andia, M Chakhtoura, P Ebeling, G El Hajj Fuleihan, A El Maghraoui, J Foldes, C Glüer, G Guglielmi, G Holzer, D Kendler, N Napoli, R Schmiedmaier, T de Villiers.

To define and assess the effects on bones following a cancer or cancer treatment.

• Monoclonal gammopathy of undetermined significance (MGUS) and Bone Fragility and fractures
• Bone health in patients with non-metastatic prostate cancer on androgen deprivation therapy (ADT)

1. Confavreux, C. B., et al. Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement. Osteoporosis International (2026).
2. Marcucci, G., et al. Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?. Osteoporosis International (2026).
3. Teissonnière, M., et al., Bone Effects of Anti-Cancer Treatments in 2024. Calcif Tissue Int 116, 54 (2025).
4. Kendler, D.L., et al. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.
   J Bone Oncol . 2021 23;28:100361.
5. Marcucci, G., et al., Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Ann Oncol, 2019. 30(6): p. 908-920.
6. Kendler, D.L., et al., Bone management in hematologic stem cell transplant recipients. Osteoporosis International, 2018. 29(12): p. 2597-2610.
7. Cianferotti, L., et al., The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 2017. 8(43): p. 75646-75663.
8. Rizzoli, R., et al., Cancer-associated bone disease. Osteoporosis International , 2013. 24(12): p. 2929-53.